Cue Biopharma, Inc.
CUE Real Time Price USDRecent trades of CUE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CUE's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
CUE Revenue by Segment or Geography
New patents grants
-
Patent Title: Multimeric t-cell modulatory polypeptides and methods of use thereof Mar. 25, 2025
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 31, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 26, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 19, 2024
-
Patent Title: Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof Jul. 09, 2024
-
Patent Title: T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof Jun. 11, 2024
-
Patent Title: Methods for modulating an immune response May. 28, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof May. 21, 2024
-
Patent Title: Methods for modulating an immune response Apr. 16, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 20, 2024
-
Patent Title: Multimeric t-cell modulatory polypeptides and methods of use thereof Jan. 23, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
-
Patent Title: Methods for modulating an immune response Sep. 26, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 29, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 25, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides Jul. 18, 2023
-
Patent Title: Tgf-β polypeptides Jul. 04, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 20, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: Methods for modulating an immune response Oct. 25, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 02, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 05, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jun. 28, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Sep. 14, 2021
-
Patent Title: Methods for modulating an immune response Aug. 31, 2021
-
Patent Title: Methods for modulating an immune response Feb. 23, 2021
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 23, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CUE
Recent picks made for CUE stock on CNBC
ETFs with the largest estimated holdings in CUE
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CUE stock a Buy, Sell, or Hold?
- What is the price target for $CUE stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CUE stock?
- Who owns the most shares of $CUE stock?
- What funds own $CUE stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CUE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.